The Senate Health, Education, Labor, and Pensions (HELP) Committee held a historic hearing bringing together CEOs of major insulin manufacturers (Eli Lilly, Novo Nordisk, Sanofi) and executives from the three largest PBMs (CVS Caremark, Express Scripts, OptumRx) to examine soaring insulin prices. …
Bernie SandersSenate HELP CommitteeLars Fruergaard JorgensenPaul HudsonHeather Cianfrocco+6 morehealthcarepbmpharmacyinsulindrug-pricing+2 more
In January 2017, diabetes patients filed a federal antitrust class action lawsuit alleging that the three pharmaceutical manufacturers controlling 99% of the U.S. insulin market—Eli Lilly, Novo Nordisk, and Sanofi—conspired to raise insulin prices in near-lockstep coordination, increasing prices by …
Eli LillyNovo NordiskSanofiCVS CaremarkExpress Scripts+1 morehealthcarepharmaceutical-price-gougingantitrustcorporate-crimeregulatory-capture
The average price of insulin in the United States began a decade-long tripling from $231 per patient annually in 2002 to $762 in 2013, according to congressional hearing data—with some patients paying up to $900 per month for insulin products that cost $4.34 per milliliter in 2002 but reached $12.92 …
Eli LillyNovo NordiskSanofiCongressional Diabetes CaucusBig Pharmapharmaceutical-industrydrug-pricinghealthcaremonopolyinsulin-crisis+1 more